Authored by James Sheppard
The venture capital giant Atlas Ventures announced that it has launched a newly formed biotech called Raze Therapeutics. Raze will be based in the Boston Biotech Cluster.
Atlas was not alone in funding the company and was joined by Novartis, MPM Capital Management, MS Ventures, Partners Innovation Fund and Astellas Venture Management. Atlas has put in place its Partner Peter Barrett as Chairman and Atlas partner Jason Rhodes will take the helm as interim CEO.
Raze Therapeutics will use its knowledge to develop drugs that disrupt the anabolic pathway that cancer uses to sustain itself and grow in a variety of ways, including building biomass. This platform has the potential to treat a variety of tumours and haematological malignancies. Raze will have the chance to develop its own pipeline as well as partnering with other companies.
Jason Rhodes, interim CEO said, ‘Aberrant growth and the accumulation of biomass are hallmarks of cancer. Raze targets newly identified pathways that are essential to this anabolic metabolism and tumor survival. We have created a powerful drug discovery platform and are rapidly advancing programs directed to solid tumors and hematological malignancies.’
Raze brings together three prominent researchers in this area namely: Dr Joshua Rabinowitz of Princeton, Dr Vamsi Mootha of Massachusetts General Hospital and Dr David Sabatini of the Whitehead Institute. The scientific expertise and stellar list of backers stands Raze in good stead to tackle this extremely challenging area.